louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02738710: Comparison of Post-operative Pain at Umbilical Wound After Laparoscopic Cholecystectomy With Transumbilical Versus Infraumbilical Incision
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Gallstone
Lead sponsor: Thammasat University
Sponsor class: OTHER
First posted: 2016-04-14
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compare outcomes (i.e. pain, wound infection, and patient satisfaction) between infra-umbilical vs. trans-umbilical incision after Laparoscopic cholecystectomy

Detailed description: Infra-umbilical wound have been used for a while with aim at improving cosmoses of the incision. Formerly, standard incision for laparoscopic cholecystectomy was infra-umbilical wound. However, no study directly compare these types of incisions in term of postoperative pain, wound infection, and patient satisfaction.

Eligibility criteria: Inclusion Criteria:

* elective laparoscopic cholecystectomy
* willing to participate

Exclusion Criteria:

* pregnancy
* immunocompromised host
* on continuous ambulatory peritoneal dialysis
* morbid obesity (Body mass index \> 35 kg/m2)
* End-stage renal disease with hemodialysis dependent
* ascites
* uncontrolled coagulopathy

Primary outcomes:
measure: Postoperative pain
timeFrame: 7 days postoperatively
Secondary outcomes:
measure: wound infection
timeFrame: at 1 week and 1 month postoperatively
measure: patient satisfaction
timeFrame: 1 week and 3 months postoperatively
Other outcomes:
Locations:
city: Khlong Luang
country: Thailand
facility: Thammasat University Hospital
state: Pathumtani
Study officials:
affiliation: Thammasat University Hospital
name: Trilak Chunsurisap
role: STUDY_CHAIR
References:
citation: Siribumrungwong B, Chunsirisub T, Limpavitayaporn P, Tongyoo A, Sriussadaporn E, Mingmalairak C, Thowprasert W, Thakkinstian A. Comparison of postoperative pain at umbilical wound after conventional laparoscopic cholecystectomy between transumbilical and infraumbilical incisions: a randomized control trial. Surg Endosc. 2019 May;33(5):1578-1584. doi: 10.1007/s00464-018-6447-y. Epub 2018 Oct 22.
Clinical trial NCT05645510: LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Official title: LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Tyrosine Kinase Mutation
Breast Cancer
Melanoma
Multiple Myeloma
Chronic Leukemia
Prostate Cancer
Ovarian Cancer
Colorectal Cancer
Lung Cancer
Lead sponsor: University of Alberta
Sponsor class: OTHER
Collaborators: name: Social Sciences and Humanities Research Council of Canada
First posted: 2022-12-09
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: people with cancer taking oral anti-cancer agents over the long term

Brief summary: People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Detailed description: Participants ill be scheduled for an in-person, telephone or computer video interview with the researcher(s). They will be asked about their experiences receiving targeted anti-cancer treatments. Then over the next 3 months, participants will be asked to think about how receiving these cancer treatments affects daily living and to create a 'metaphor'. Metaphors may be composed with any mix of visual, verbal, musical or other works participants feel expresses and brings their experiences to life.

Eligibility criteria: Inclusion Criteria: taking chronic targeted anti-cancer agents -

Exclusion Criteria:

-

Primary outcomes:
measure: Interview
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: Edith Pituskin
state: Alberta
Study officials:
References:
Clinical trial NCT03197610: The Effect of Enamel Matrix Derivatives on Root Coverage Esthetic Score
Official title: The Effect of Enamel Matrix Derivatives on Root Coverage Esthetic Score
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingival Recession
Periodontal Diseases
Keywords: gingival recession
sub epithelial connective tissue graft
enamel matrix derivatives
root coverage aesthetic score
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2017-06-23
Enrollment: 19
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Subepithelial connective tissue grafts (SCTG) are accepted as the gold standard in covering denuded root surfaces. Combining enamel matrix derivatives (EMD) with periodontoplasic surgical operations is another method in covering denuded root surface. The aim of this study is to compare a SCTG operation group and EMD applied group in addition to SCTG using complete root coverage rate and a newer method root coverage esthetic scoring system (RES).

Detailed description: Background: Subepithelial connective tissue grafts (SCTG) are accepted as the gold standard in covering denuded root surfaces. Combining enamel matrix derivatives (EMD) with periodontoplasic surgical operations is another method in covering denuded root surface. The aim of this study is to compare a SCTG operation group and EMD applied group in addition to SCTG using complete root coverage rate and a newer method root coverage esthetic scoring system (RES).

Methods: This is a split-mouth and controlled study. Thirthy-eight Class I or II gingival recession defects at canine teeth were treated in the control (SCTG) (n=19) and test groups (n=19) (SCTG+EMD). The root coverage esthetic score were evaluated by 2 blind periodontists 1 year after the treatment using RES. The agreement between the two periodontists was assessed by kappa analysis. Complete root coverage rate was evaluated for both groups. Two groups were compared with statistically methods in terms of RES parameters and gingival recession height /width.

Eligibility criteria: Inclusion Criteria:

* The patient had no systemic disease, did not smoke cigarette and tobacco products, did not have a pregnancy and breastfeeding period, had class I and class II gingival recession according to the Miller gingival classification, had a recession depth of ≥2 mm, have not had a restoration and have had an operation in the relevant dental region that had no previous gingival surgical procedure were included in this study.

Exclusion Criteria:

* systemic disease
* multiple gingival recession
* miller class III and IV recessions were excluded

Primary outcomes:
measure: root coverage percentage
timeFrame: 1 year
measure: root coverage aesthetic score
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05480410: Effectiveness of rTMS on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial.
Official title: Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neuropathic Pain
Keywords: Transcranial Magnetic Stimulation, Repetitive
Neuropathic pain
Quality of life
Cancer
Lead sponsor: Fundacion Universitaria Maria Cano
Sponsor class: OTHER
First posted: 2022-07-29
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A single group including patients with neuropathic oncological pain.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness of Repetitive transcranial magnetic stimulation (rTMS) on pain and quality of life in patients with cancer neuropathic pain.

Although there are currently different therapeutic options for neuropathic pain, most are limited or restricted to pharmacotherapy. Transcranial magnetic stimulation (TMS) is a tool recently incorporated into neuroscience in the management of neuropathic cancer pain.

The study will include 10 patients with oncologic neuropathic pain who will receive 20 sessions of rTMS and the effect on pain and quality of life.

Detailed description: Neuropathic pain is defined as pain caused by a primary lesion or transient dysfunction of the central or peripheral nervous system. In cancer, it is generated as a consequence of multiple factors such as: direct compression of nerve structures, post-surgical nerve injuries, and nerve injuries secondary to chemotherapy. At least 3.5 million people around the world suffer from this symptom associated with cancer; Of this population, 38% experience pain in all stages and 80% in advanced stages, negatively impacting quality of life.

Eligibility criteria: Inclusion Criteria:

* Patients with neuropathic pain of oncological origin
* Patients of legal age (18 years old)
* Patients using their cognitive faculties

Exclusion Criteria:

* Pregnancy
* History of negative reaction to TMS
* History of seizure, history of epilepsy stroke, brain surgery and cranial metal implants.

Primary outcomes:
measure: Effect of Change of 20 rTMS Sessions on Pain
timeFrame: Day 1 vs Day 20 vs 1st month follow up and vs 3rd month follow up
measure: Effect of Change of 20 rTMS Sessions on Pain and Functionality
timeFrame: Day 1 vs Day 20 vs 1st month follow up and vs 3th month follow up
Secondary outcomes:
measure: Effect of Change of 20 rTMS Sessions on Quality of Life
timeFrame: Day 1 vs Day 20 vs 1st month follow up and vs 3rd month follow up
Other outcomes:
Locations:
city: Medellín
country: Colombia
facility: CORTEX
state: Antioquia
Study officials:
affiliation: Fundacion Universitaria Maria Cano
name: Catalina Lopera, Msc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00978510: Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment
Official title: Health Personnel and the Control of Tuberculosis in a Hospital Environment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Health Care Professionals
Hospital Environment
Keywords: Tuberculosis
Disease transmission
Exposure to biological agents
Health personnel
Lead sponsor: Sociedade Cearense de Infectologia
Sponsor class: OTHER
First posted: 2009-09-17
Enrollment: 159
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Health care professionals from a public hospital in Brazil

Brief summary: The purpose of this study is to evaluate in hospital environment the knowledge of the health care professionals about fundamental concepts on tuberculosis and the accomplishment to respiratory isolation practices for patients with pulmonary tuberculosis hospitalized in a public hospital in Fortaleza, Ceará, Brazil.

Detailed description: A cross-sectional study of health care professionals using a study instrument with questions to evaluate the knowledge of basic concepts about tuberculosis. A retrospective study reviewing medical records of patients with suspected tuberculosis hospitalized in the units of Adult and Pediatric Clinics and in the Critical Care Unit in a general hospital in Fortaleza-CE.

Eligibility criteria: Inclusion Criteria:

* Health care professionals working in a public hospital (HGWA) in the units of Adult and Pediatric Clinics and in the Critical Care Unit in a general hospital in Fortaleza-CE

Exclusion Criteria:

* Health care professionals working in HGWA but in units other than Adult and Pediatric Clinics and in the Critical Care Unit

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fortaleza
country: Brazil
facility: Hospital Geral Dr. Waldemar Alcântara
state: Ceará
Study officials:
affiliation: Universidade Federal do Ceará - UFC
name: Roberto J Pires Neto
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01718210: Use of GM-CSF Supplemented IVF Medium in Patients With Recurrent Implantation Failure
Official title: GM-CSF Supplemented Medium for IVF Embryo Growth in Patients With Recurrent Implantation Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Keywords: GM-CSF
recurrent implantation failure
pregnancy rate
IVF
Lead sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Sponsor class: NETWORK
First posted: 2012-10-31
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether in Assisted Reproductive Technologies the use of culture medium supplemented with GM-CSF, a growth factor working on stem cells, may improve the embryo implantation in patients experiencing recurrent implantation failure in IVF cycles.

Detailed description: In Assisted Reproductive Technologies the rate of pregnancy for cycle and the implantation rate remain low nevertheless the improvement in the last years. In particular there are a group of patients, in young reproductive age, experiencing recurrent implantation failure, nevertheless the good embryos produced and transferred. Recently, it has been showed that culture medium supplemented with GM-CSF, may improve the embryo outcomes in IVF. In this trial the investigators will test the potential benefits of this culture medium on embryos of patients experiencing recurrent implantation failure. 100 women with recurrent implantation failure, at least three failed previous IVF attempts with at least 8 good embryos transferred no more than 40 years old will be selected. These patients will be assigned to two arms, one experimental and one other of control by a computer generated sequence. After the oocyte retrieval and fertilization by ICSI procedure, the fertilised oocyte (2PN)will cultured with the GM-CSF supplemented culture medium (EmbryoGen, Origio, Denmark), or in normal culture in micro drop of 30microliters under oil until the day of transfer (day three or 8 cells sage embryos). A maximum of three embryos will be transferred. The pregnancy rate the implantation rate will be the outcomes considered

Eligibility criteria: Inclusion Criteria:

* woman age 40 years old or less,
* 3 or more consecutive previous failed IVF cycles with a total of at least 8 good embryos replaced in uterus

Exclusion Criteria:

* chromosomal defects in the couple,
* metabolic diseases (diabetes, etc),
* other genetic diseases (thalassemia, cystic fibrosis, etc.)

Primary outcomes:
measure: Pregnancy rate
timeFrame: 9 months
Secondary outcomes:
measure: Implantation rate
timeFrame: 9 months
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Villa Salaria Fisiopatologia Riproduzione
Study officials:
affiliation: Centre for Endocrinology and Reproductive Medicine, Italy
name: Marco Sbracia, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05128110: Study of Hemostasis During the Atrial Fibrillation Ablation Procedure
Official title: Study of Hemostasis During the Atrial Fibrillation Ablation Procedure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemostasis
Keywords: Atrial fibrillation
Ablation
ACT
Heparin
Direct oral anticoagulant
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2021-11-19
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient with an atrial fibrillation, perated for an atrial fibrillation procedure in the University hospital of Strasbourg and without interruption of the direct oral anticoagulant

Brief summary: Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial fibrillation) was interrupted a few days before the procedure in order to limit the risk of per-procedural bleeding. However, 3 recent randomized studies concerning the 3 DOACs available suggest that treatment should not be interrupted during the entire operative period. The operation therefore takes place under double anticoagulation with a direct oral anticoagulant and unfractionated heparin. Under these conditions, ACT monitoring can no longer be considered a reliable means of measuring the level of anticoagulation. It was therefore necessary to explore the hemostasis of these patients in a broad way in order to avoid any risk of overdose of UFH (Unfractionated Heparin) during the procedure.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years-old
* with an atrial fibrillation
* Operated for an atrial fibrillation procedure in the University hospital of Strasbourg
* Without interruption of the direct oral anticoagulant
* For whom extended biological assessment has been made in routine practice

Exclusion Criteria:

* Patients who refused the use of their data for this study

Primary outcomes:
measure: Study of hemorrhagic and thrombotic complications and correlation with the various laboratory tests
timeFrame: Files analysed retrospectively from January 01, 2019 to December 31, 2019 will be examined]
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
Study officials:
affiliation: Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
name: Charles-Ambroise TACQUARD, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04032210: The Influence of Preventive Regimens Containing Different Toothpastes on Caries Risk of High Risk Patients: A Randomized Clinical Trial
Official title: The Influence of Preventive Regimens Containing Different Toothpastes on Caries Risk of High Risk Patients: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Prevention of Dental Caries
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-07-25
Enrollment: 66
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: 66 Participants will be divided into three groups according to the tested regimen (A), where (A1) represents participants will be exposed to regimen including dual zinc plus arginine based toothpaste (Colgate total), (A2) represents participants will be exposed to regimen including zinc based toothpaste (Crest complete) and (A3) represents control group where participants will be used fluoride based toothpaste (Signal). The study will be carried over a period of one year, assessment of cariogram will be done in two visits: first visit (baseline: T0) and second visit (after 3 months: T3) . In addition assessment of DMF scores will be done in four visits: first visit (baseline: T0), second visit (after 3 months: T3), third visit (after 6 months: T6) and final visit (after 12 months: T12) to obtain the required data


Eligibility criteria: Inclusion Criteria:

* • Normal adults will be recruited in this study, all the volunteers participated in this experiment will be healthy looking with free medical history.

  * Subjects of mean age 20-50 years.
  * Patients with high caries risk assessment according to Cariogram.
  * Non cariogenic diet patient
  * High plaque index
  * Not under antibiotic therapy either at the time of the study or up to the last month before the start of the study.

Exclusion Criteria:

* • Patients with a compromised medical history.

  * Cariogenic diet patient.
  * Participants with severe or active periodontal disease.
  * Participants with a history of allergy to any of the drugs or chemicals used in the study.
  * Patients on any antibiotics during the past month

Primary outcomes:
measure: caries risk assessment
timeFrame: Three months
Secondary outcomes:
measure: DMF score
timeFrame: 12 months
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Esraa Abdel Ghaffar Ahmed
state: Other
Study officials:
References:
Clinical trial NCT02366910: Dehydration of Omafilcon A Contact Lenses Versus Delefilcon A Contact Lenses
Official title: Dehydration of Omafilcon A Contact Lenses Versus Delefilcon A Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Lead sponsor: CooperVision International Limited (CVIL)
Sponsor class: INDUSTRY
First posted: 2015-02-19
Enrollment: 26
Sex: ALL
Minimum age (years): 17
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study will explore in vivo lens dehydration rates across a 12hr wear period for the study lenses.

Detailed description: The study will explore in vivo lens dehydration rates across a 12hr wear period for the study lenses. The primary outcome variable for this study is the loss in lens weight over the day, which will indicate the amount of dehydration that has occured.

Eligibility criteria: Inclusion Criteria:

1. Is at least 17 years of age and has full legal capacity to volunteer;
2. Has read and signed an information consent letter;
3. Is willing and able to follow instructions and maintain the appointment schedule;
4. Is a current wearer of soft contact lenses and has worn them (any brand) more than 3 months.
5. Is able to wear lenses for at least 12 hours a day.

Exclusion Criteria:

1. Is participating in any concurrent clinical study;
2. Has any known active\* ocular disease and/or infection;
3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
4. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
5. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
6. Has undergone refractive error surgery;

   * \*For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Primary outcomes:
measure: Absolute Change in Water Content (Mean) of Omafilcon A and Delefilcon A
timeFrame: 12 Hours of Wear
measure: Absolute Change in Water Content (Median) of Omafilcon A and Delefilcon A
timeFrame: 12 Hours of Wear
measure: Moisture Retention (Mean) of Omafilcon A and Delefilcon A
timeFrame: 12 Hours
measure: Moisture Retention (Median) of Omafilcon A and Delefilcon A
timeFrame: 12 Hours
Secondary outcomes:
Other outcomes:
Locations:
city: Waterloo
country: Canada
facility: University of Waterloo School of Optometry
state: Ontario
Study officials:
affiliation: Director, Centre for Contact Lens Research
name: Lydon Jones, PhD FC
role: PRINCIPAL_INVESTIGATOR
affiliation: Univerisy of Waterloo
name: Farah Panjwani, BSc RAQ
role: PRINCIPAL_INVESTIGATOR
References: